Por Renan Filho · 2026-10-01**Lead**
The kratom industry is pushing back against what it calls a dangerous conflation in the ongoing federal regulatory debate: the use of the term “kratom” to describe synthetic opioids. In a series of statements and filings with the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA), industry representatives argue that labeling synthetic compounds—often far more potent and unpredictable—as “kratom” misleads consumers, distorts the scientific record, and could lead to overly restrictive policies that punish the natural botanical product.
**Context**
Kratom, derived from the leaves of the *Mitragyna speciosa* tree native to Southeast Asia, has been used for centuries as a mild stimulant and pain reliever. In the United States, it is sold as a dietary supplement and has gained a following among people seeking alternatives to prescription opioids for chronic pain or to manage withdrawal symptoms. However, the FDA has repeatedly warned that kratom carries risks, including addiction and potential for abuse, and has linked it to dozens of deaths—though many of those cases involved adulterated products or poly-drug use.
In recent years, a new concern has emerged: synthetic compounds designed to mimic or enhance kratom’s effects. Some of these substances, such as synthetic mitragynine analogs, are being produced in illicit laboratories and sold online, sometimes under the umbrella term “kratom.” Industry groups, including the American Kratom Association (AKA), say this is a critical misnomer. The AKA has filed comments with the FDA arguing that synthetic opioids should be classified and regulated separately from natural kratom, and that using the same name creates confusion for law enforcement, healthcare providers, and consumers.
The issue has gained urgency as the DEA considers whether to place kratom itself under Schedule I of the Controlled Substances Act—a move that would effectively ban the plant. Industry advocates warn that if synthetic analogs are lumped into the same category, it could trigger a blanket prohibition that ignores the distinct chemical profiles and risk levels of natural versus synthetic products.
**Analise**
The stakes of this labeling dispute extend beyond semantics. If regulators accept the industry’s argument, they would need to craft separate regulatory pathways for natural kratom and its synthetic counterparts—a complex task that would require new testing standards, labeling requirements, and enforcement mechanisms. Conversely, if the term “kratom” continues to be used broadly, the industry fears that a single high-profile incident involving a synthetic opioid could spark a public backlash that destroys the market for the natural product.
Public health experts are divided. Some argue that the industry’s concern is self-serving—an attempt to shield kratom from scrutiny by distancing it from more dangerous synthetics. Others note that accurate terminology is essential for effective regulation. The FDA has not yet issued a formal position on the labeling question, but internal documents suggest the agency is aware of the distinction. In a 2024 advisory, the FDA warned consumers about “synthetic kratom-like substances” but did not explicitly forbid vendors from using the term.
The political dimension is equally significant. Several members of Congress have introduced bills that would regulate kratom at the federal level, with some proposals explicitly defining kratom as the natural plant and others using broader language. The industry is lobbying for the narrower definition, arguing that it aligns with scientific consensus and protects consumer access. Meanwhile, law enforcement agencies have expressed concern that any regulatory gap could be exploited by illicit manufacturers.
**Fontes**
- American Kratom Association (AKA) public comments to the FDA, 2025-2026. - U.S. Food and Drug Administration, “FDA Warns About Synthetic Kratom-Like Substances,” 2024. - Drug Enforcement Administration, “Kratom and Synthetic Opioids: Regulatory Considerations,” 2025. - Congressional testimony from industry representatives and public health officials, 2025-2026. - Published scientific literature on kratom pharmacology and synthetic analogs (e.g., *Journal of Medicinal Chemistry*, 2023).